Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma
Authors:
- 1 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 51 (6) , 684-693
Abstract
Objectives: Pharmacological ascorbate (P-AscH−, high-dose, intravenous vitamin C) has shown promise as an adjuvant therapy for pancreatic ductal adenocarcinoma (PDAC) treatment. The objective of this study was to determine the effects of P-AscH− when combined with PDAC chemotherapies. Methods: Clonogenic survival, combination indices, and DNA damage were determined in human PDAC cell lines treated with P-AscH− in combination with 5-fluorouracil, paclitaxel, or FOLFIRINOX (combination of leucovorin, 5-fluorouracil, irinotecan, oxaliplatin). Tumor volume changes, overall survival, blood analysis, and plasma ascorbate concentration were determined in vivo in mice treated with P-AscH− with or without FOLFIRINOX. Results: P-AscH− combined with 5-fluorouracil, paclitaxel, or FOLFIRINOX significantly reduced clonogenic survival in vitro. The DNA damage, measured by γH2AX protein expression, was increased after treatment with P-AscH−, FOLFIRINOX, and their combination. In vivo, tumor growth rate was significantly reduced by P-AscH−, FOLFIRINOX, and their combination. Overall survival was significantly increased by the combination of P-AscH− and FOLFIRINOX. Treatment with P-AscH− increased red blood cell and hemoglobin values but had no effect on white blood cell counts. Plasma ascorbate concentrations were significantly elevated in mice treated with P-AscH− with or without FOLFIRINOX. Conclusions: The addition of P-AscH− to standard of care chemotherapy has the potential to be an effective adjuvant for PDAC treatment.Keywords
This publication has 50 references indexed in Scilit:
- Manganoporphyrins Increase Ascorbate-Induced Cytotoxicity by Enhancing H2O2 GenerationCancer Research, 2013
- Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicityFree Radical Research, 2013
- Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerFree Radical Biology and Medicine, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic CancerClinical Cancer Research, 2010
- Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProceedings of the National Academy of Sciences, 2008
- A simple and sensitive assay for ascorbate using a plate readerAnalytical Biochemistry, 2007
- Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProceedings of the National Academy of Sciences, 2007
- The Pecking Order of Free Radicals and Antioxidants: Lipid Peroxidation, α-Tocopherol, and AscorbateArchives of Biochemistry and Biophysics, 1993
- Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligandsJournal of Theoretical Biology, 1976